Articles in category "Latest News"

March 19, 2015

Timed Auction To Take Place March 20-25, 2015 SAN DIEGO—Mar. 19, 2015—BioSurplus, America’s leader in used lab equipment, announced today that it will be holding a timed online auction of biotech / biopharma equipment from laboratory closures in Cambridge, MA, San Diego, CA, and Seattle, WA. The online auction will run from March 20-25, 2015. Available research and development assets from these laboratories span a range of analytical technologies, including mass spectrometry, robotic liquid handling, and GPCR screening. Included among the lots are high-end instruments such as: – Thermo Scientific LTQ Orbitrap Hybrid Mass Spectrometer – Hamilton Microlab STARlet Automated […]

February 24, 2015

SAN DIEGO–(BUSINESS WIRE)–BioSurplus, America’s leader in used lab equipment, announced today that it will be holding a timed online auction of lab equipment from AVEO Oncology’s discontinued research facility in Cambridge, Mass. The online auction will run from March 10-17, 2015. Located in the heart of the Kendall Square biotechnology supercluster, AVEO’s laboratory facility contains approximately 400 lots of biotech research equipment that will be available for auction. Available equipment can be viewed during an on-site, open house event at 650 East Kendall Street, Cambridge, MA 02142 on Thursday, March 5 from 9 a.m. to 5 p.m. and Friday, March […]

October 22, 2014

SAN DIEGO, Oct. 23, 2014—BioSurplus, America’s leader in used lab equipment, announced today that it will be holding a second auction of lab equipment from Lexicon Pharmaceuticals’ drug discovery and pre-clinical research facility in The Woodlands, TX. The online auction will run from October 23–30, 2014. As Lexicon Pharmaceuticals has refocused on clinical programs, approximately 1,300 more lots of research and development equipment will be available in auction. Available lots include late-model biosafety cabinets, refrigerated centrifuges, research microscopes, vivarium equipment, behavioral studies equipment, consumables and other basic biotech equipment. Among the lots are high-end items including: – Applied Biosystems 3730xl […]

September 9, 2014

SAN DIEGO, Sept. 9, 2014—BioSurplus, America’s leader in used lab equipment, announced today that it will be holding an auction of lab equipment from Lexicon Pharmaceuticals’ drug discovery, validation and pre-clinical research facility in The Woodlands, TX. The online auction will run from October 2 – 9, 2014. Items can be viewed on site at 8800 Technology Forest Place, The Woodlands, TX 77381-1160 on September 25 from 8 a.m. to 6 p.m, and on September 26 from 8 a.m. to 3 p.m. As Lexicon Pharmaceuticals has refocused on clinical programs, approximately 1000 lots of research and development equipment will be […]

June 28, 2014

Last November, BioSurplus’ VP of business development, Dawn Hocevar was interviewed by Ed Miseta, chief editor of Outsourced Pharma. The piece was part of a series of interviews with women executives in the biotech and pharma industries sponsored by the organization Women In Bio (WIB). Hocevar, in addition to her role at BioSurplus is also currently serving as WIB’s national chair of programs and development, where she works with local chapters to execute programs that promote careers, leadership and entrepreneurship for women in the life sciences. Over her 20-plus year career, Dawn Hocevar has developed a deep knowledge of laboratory […]

June 19, 2014

Are you heading to San Diego for BIO 2014 next week? If so, do you know how you’re going to spend your free time while you’re here? With so much to do during the conference itself, that free time just might be limited. But if you do have a chance to get away, San Diego offers some great places for you to spend it. And it’s not all about the beach and surfing…. Jennifer Landress, Senior VP and COO of BIOCOM, recently posted an excellent list of local attractions on the BIOtechNOW blog. BioSurplus is a BIOCOM member and a […]

June 16, 2014

Basel, Switzerland-based pharma giant Roche announced on June 2 that it has acquired Genia Technologies of Mountain View, CA, a next-gen sequencing technology company whose nanopore-based platform allows for rapid DNA sequencing using integrated circuits. BioSurplus’ Antonio Johnson previously wrote about Genia’s technology on the BioSurplus blog. Take a moment to read the article here. The $125 million acquisition, with a potential further payout of $225 million to investors upon completion of certain milestones, is part of Roche’s plan to develop its own sequencing platform on which it can base its diagnostic products. The company bought 454 Life Sciences, an […]

June 13, 2014

The J. Craig Venter Institute (JCVI) announced on Thursday, June 5, that it has been awarded a grant of approximately $25 million from the National Institute of Allergy and Infectious Diseases (NAID). The funding, to be provided over a five-year period, will enable the establishment and operation of a Genome Center for Infectious Diseases (GCID). The center’s primary goal will be to further the scientific understanding of infectious diseases by focusing on the pathogens that cause them. Research results will be made available to the greater scientific community. Infectious diseases continue to be a worldwide scourge and are one of […]

June 9, 2014

For the first time, researchers have used next-gen DNA sequencing to make an actionable diagnosis on a patient. A report of the case was published in an article in the New England Journal of Medicine this Wednesday, June 4. 14-year old Joshua Osborne, of Madison Wisconsin, had been placed in a medically induced coma last July due to severe swelling in his brain. When testing for multiple diseases turned up nothing, his doctor, James Gern, of the University of Wisconsin School of Medicine, reached out to two of his fellow research collaborators: Dr. Joseph DeRisi, and his colleague, pathologist Dr. […]

June 6, 2014

San Diego-based Halozyme Therapeutics announced on Wednesday that the FDA has lifted a hold on a clinical trial of its pancreatic cancer drug, PEGPH20. The hold on patient enrollment and dosing was put in place this April when the company, based on recommendations from an independent data monitoring committee, decided to evaluate a possible increase in the rate of thromboembolism, or blood clots, in patients treated with PEGPH20. After reviewing data, the committee recommended last month that the trial (Study 202) be resumed under revised protocols. Patients considered to be at a high risk of thromboembolic events will be excluded […]